A Phase 2b Extension Study of PTC124 as an Oral Treatment for Nonsense-Mutation-Mediated Cystic Fibrosis.

Trial Profile

A Phase 2b Extension Study of PTC124 as an Oral Treatment for Nonsense-Mutation-Mediated Cystic Fibrosis.

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Aug 2014

At a glance

  • Drugs Ataluren (Primary)
  • Indications Cystic fibrosis
  • Focus Pharmacogenomic; Therapeutic Use
  • Sponsors PTC Therapeutics
  • Most Recent Events

    • 07 Aug 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top